Eric Crampon

Dr. Eric Crampon is an innovative scientist and biotechnology leader with over a decade of experience in biochemistry, molecular biology, and biologics development. He holds a Ph.D. in Structural Biochemistry from the Institut Pasteur (Paris), where he investigated viral protein assembly and structural determinants of immunogenicity (ResearchGate profile).

As Associate Director at Takeda Pharmaceuticals, Dr. Crampon led analytical development for global vaccine programs, including the dengue vaccine Qdenga®. He directed teams responsible for critical reagent design, analytical method validation, and CMC integration, bridging R&D and regulatory strategy. He previously held analytical and bioassay roles at Novartis Vaccines and Vertex Pharmaceuticals (LinkedIn).

Dr. Crampon’s research record spans protein biochemistry, ligand-binding assay development, and nanobody engineering, available via his ResearchGate publications. His work focuses on merging structural biology and computational analytics to improve reproducibility and scalability in biologics characterization.

He is currently the founder of Adam & Snakes, an independent venture developing fully synthetic, single-domain antibody (sdAb) antivenoms as a cruelty-free, scalable alternative to plasma-derived products. This work aims to demonstrate that in vitro–selected sdAbs can neutralize snake venoms as effectively as traditional antibodies. In 2025, Dr. Crampon will discuss this platform concept at the 2nd Workshop on Translational Venom Medicine, joining experts from Fiocruz and Butantan Institute to advance synthetic antivenom research and collaboration.

October 2025